Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
about
Gene therapy for hemophiliaThe stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein.Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain.Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector.Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia ADirected engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Integration site choice of a feline immunodeficiency virus vector.piggyBac-mediated phenotypic correction of factor VIII deficiencyDelivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.Perinatal gene transfer to the liver.Development and Applications of VSV Vectors Based on Cell TropismA Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA TransposonMolecular characterization of feline immunodeficiency virus budding.Genetic engineering for haemophilia A.Evading the immune response upon in vivo gene therapy with viral vectors.Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.Human gene therapy vectors derived from feline lentiviruses.Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cellsThe role of liver sinusoidal cells in hepatocyte-directed gene transfer.Recent advances in lentiviral vector development and applications.Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy.New developments in lentiviral vector design, production and purification.Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64.Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice.Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.Analysis of factor VIII mediated suppression of lentiviral vector titres.Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade.Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.MAFA missense mutation causes familial insulinomatosis and diabetes mellitus.Lentiviral-mediated gene transfer – a patent reviewBaculovirus vector for gene delivery and vaccine development
P2860
Q28081911-B9263B40-CBA7-49D6-B134-8704631A9EFDQ30440686-36CE83E2-D815-42F7-846C-2D8091D714D3Q33509166-01A5002F-4C5D-4CCB-A902-4FB995C2ACC0Q33565275-C9CA1B2A-E11A-46B5-8027-280B1E43BBCEQ33688429-53241569-8F11-47AD-822C-CBA0DE0CA89BQ33713758-72BDBB2F-C24B-4D16-844A-96E95959A8F5Q35001971-D98081EC-AD37-43C1-8E51-17A149FC743DQ35024080-2DD60B9A-4B07-44D1-92AD-C5E2A0F31BB2Q35184221-9DE374DB-BD24-443F-A93B-8A505A40336CQ35225590-A08C57A0-28BF-4CBE-86C2-C02DB6ADD0ADQ35238390-AFD4A306-42DC-4523-A9D9-461744FE641FQ35679152-E3180A4A-3D19-40A8-ADD8-FBF93995BE3BQ36403754-AE718404-078B-4174-90C0-D1F55DAA5B98Q36483903-31B2C94F-86F9-4C60-A53B-ED8652F23CA6Q36600245-BCED879E-1CCC-41AA-8017-6D84BC84DD41Q36644230-92DBD900-7995-4FDD-81DF-9533501EA7ECQ36801646-84AD8146-725D-4776-9266-D406E010DDF9Q37090721-49A8CCEF-B7DF-4436-8E7D-213FF078C535Q37601026-C7B29AA5-86BD-43AC-9770-D67A52A5F6F7Q37641568-3D7BE28D-6024-4A85-899F-4B660D5CD5ADQ37678176-D72A84C5-EB56-4639-95E1-921EC9A433CFQ37965158-07739925-3E94-4B13-99A3-3DAB5A805C55Q38099382-412C7BAD-E3E8-4945-9D79-E7B81694E8AAQ39609813-9C40434A-5E0B-4945-A033-F5A1166E585EQ39877042-87A9BCD3-2ADB-4C1F-A16E-253F38D84A65Q40041724-4D88C7CD-3604-4BFC-B645-F598117F20F5Q40043107-A89D819A-4716-47AE-A765-627E606F9D7CQ40054535-CDBA98E8-7A9F-4B35-9E74-D5CD8561E1BFQ42119020-089E7D2D-C2F8-4003-B6F3-B9C4D893C1AFQ42209182-0EB0925C-E07D-4EA5-84D0-CEB96F9807EBQ42709633-6F34D061-4FD5-45F4-AC8F-D3FDF162B283Q48232244-EC2E85DA-D2CE-4825-9187-F713A4CC050DQ56787021-84B9A4DF-2870-4CE5-A5C2-AF9041F8E80CQ57064366-60267035-990E-4BE7-9F27-D294D95AF097
P2860
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Persistent expression of facto ...... mate lentiviral gene transfer.
@ast
Persistent expression of facto ...... mate lentiviral gene transfer.
@en
type
label
Persistent expression of facto ...... mate lentiviral gene transfer.
@ast
Persistent expression of facto ...... mate lentiviral gene transfer.
@en
prefLabel
Persistent expression of facto ...... mate lentiviral gene transfer.
@ast
Persistent expression of facto ...... mate lentiviral gene transfer.
@en
P2093
P2860
P1433
P1476
Persistent expression of facto ...... mate lentiviral gene transfer.
@en
P2093
Beverly L Davidson
Colleen S Stein
Diane Thi Tran
Melissa Hickey
Yubin Kang
P2860
P304
P356
10.1182/BLOOD-2004-11-4358
P407
P577
2005-05-10T00:00:00Z